CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

RidinilazoleNeutral
AI Analysis

Summary

Summit Therapeutics signed an agreement to sell its Phase 3 asset Ridinilazole to Biossil, Inc. The transaction represents a divestiture of a late-stage clinical program.

Clinical Trial Data

Phase

Phase 3

Importance:6/10
Sentiment:
0.00
asset salePhase 3divestiture
Related Companies

Read the original article

Published by yahoo_finance on July 14, 2026 11:00 AM

Read Original